Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Chronic Pain
Interventions: Mindfulness-Based Stress Reduction (MBSR), Open-Label Placebo (OLP), MBSR+OLP; Behavioral · Other
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: HIV Vaccine, HIV-1-infection
Interventions: ChAdOx1.HIVconsv62, ChAdOx1.tHIVconsv1, MVA.tHIVconsv4, MVA.tHIVconsv3, Placebo; Biological · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Glabellar Lines
Interventions: OnabotulinumtoxinA X, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Glendale, Arizona • Los Angeles, California • Newport Beach, California + 15 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AP-101, Placebo; Drug
Lead sponsor: AL-S Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Diabetes Mellitus, Chronic Kidney Disease, Diabetic Kidney Disease
Interventions: Cholecalciferol, Placebo; Dietary Supplement
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Musculoskeletal Complications, Pain
Interventions: duloxetine hydrochloride, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 714
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more

Conditions: Autism Spectrum Disorders
Interventions: Intranasal Oxytocin, Placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: COPD, Diabetes, Hypertension
Interventions: Supportive counseling, Education on SMB, Psychoeducation on ATs for maladaptive beliefs (if applicable), Psychoeducation on emotional response (if applicable); Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: AMG 127, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Lake Forest, California • Aventura, Florida

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more

Conditions: Alzheimer's Disease
Interventions: CPC-201; Drug
Lead sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc; Industry
Eligibility: 50 Years to 79 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Pain, Post Operative, Quality of Life
Interventions: Ibuprofen 600 mg, Placebo, Acetaminophen; Drug
Lead sponsor: Marquette University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Glabellar Frown Lines
Interventions: AbobotulinumtoxinA, Placebo; Biological · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Redondo Beach, California • San Diego, California • Westport, Connecticut + 8 more

Conditions: Asthma
Interventions: MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years and older
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 29
States / cities: Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more

Conditions: Atopic Dermatitis
Interventions: KHK4083, Placebo; Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Huntington Beach, California • Irvine, California • Los Angeles, California + 10 more

Conditions: Generalized Anxiety Disorder
Interventions: PD 0332334, Paroxetine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 29
States / cities: Arcadia, California • Costa Mesa, California • Escondido, California + 25 more

Conditions: Acne Vulgaris
Interventions: SB204 4%, SB204 8% or 12%, Vehicle; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Pain, Cannabis, Opioid Use, Unspecified
Interventions: Within-subject test of blinded study medications; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Inavolisib, Ribociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Anaheim, California • Palo Alto, California • Jacksonville, Florida + 8 more

Conditions: Metastatic Colorectal Cancer
Interventions: Not listed
Lead sponsor: KU Leuven; Other
Eligibility: 18 Years and older
Enrollment: 1,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Traumatic Brain Injury
Interventions: Citalopram; Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Endurance Exercise
Interventions: THC 5, Placebo; Drug
Lead sponsor: Christopher Bell; Other
Eligibility: 21 Years to 40 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: AEVI-001, Placebo; Drug
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Wayne, Pennsylvania

Search by objective public record fields.

Mindfulness And Placebo for Pain (MAPP) Study

Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART

A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS

Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders

Healthy Mediation Adherence To Transform and Effectively Relieve Symptoms

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

Preemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

Enhancing Medication-based Analgesia in Humans

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

A Non-Interventional Follow-Up to the VELOUR Study - Translational Research

Treatment of Citalopram for Anxiety Disorders Following a Traumatic Brain Injury

Influence of Edible Marijuana on Endurance Exercise Performance

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations